Week of Feb. 13th-17th, 2017
Check back often for weekly updates
Alpha-1 Foundation – Effect of Augmentation Therapy on COPD Exacerbations in Alpha-1 Antitrypsin Deficiency ($500,000 award, deadline May 8th, 2017). The purpose of this RFA is to assess the effect of intravenous augmentation therapy compared to placebo on acute pulmonary exacerbations (frequency and/or severity and/or time to first exacerbation) in patients with severe alpha-1 antitrypsin deficiency (serum alpha-1 antitrypsin level <50mg/dl when clinically stable). The Alpha-1 Foundation intends to commit up to a total of $500,000 over two (2) years to fund one (1) grant.
Alliance for Cancer Gene Therapy, Inc. – 2017 Investigator’s Award in Clinical Translation of Cell and Gene Therapy for Cancer Research Grant ($500,000 award, Letter of Intent deadline March 21st, 2017). Alliance for Cancer Gene Therapy, Inc. (ACGT) funds research aimed at furthering the development of cell and gene therapy approaches to the treatment of cancer. To this end, ACGT offers awards in Clinical Translation of Cell and Gene Therapy for Cancer, to qualified scientists at the assistant professor level and above. This award is specifically for those conducting Cell and Gene Therapy Research for Cancer and is entitled, 2017 Investigator’s Award in Clinical Translation of Cell and Gene Therapy for Cancer. The award provides up to a maximum of $500,000 distributed over 2-3 years, inclusive of a maximum of 10% indirect costs. The deadline for submission of abstracts (LOIs) is March 21, 2017.
Pfizer – multiple opportunities:
· Knowledge Gaps for Pharmacists in CDK 4/6 Therapies for Advanced or Metastatic Breast Cancer Treatment ($500,000 award, deadline March 22nd, 2017). Pharmacists are often called upon to advise other members of the care team on specifics of treatments, interactions, dosing, and side effects. They frequently need to answer patient questions and provide support throughout the breast cancer treatment journey. Proposed programs should increase the awareness and understanding of the emerging clinical and real world data for the use of CDK 4/6 inhibitors in treating patients with advanced or metastatic breast cancer. Examples of topics that could be addressed are: 1) Dosing and dose adjustments 2) Drug interactions 3) Adverse events 4) Importance of monitoring, and, 5) Lab value interpretation based on guidelines. All activity types will be considered through this CGA, including live events, satellite symposia, workshops, online courses, print materials, and other enduring materials including published proceedings. Efforts should be made to encourage interaction, incorporate patient case discussions, and provide opportunities to extend and reinforce learning opportunities beyond the live setting.
· Advanced or Metastatic Breast Cancer Treatment: Real World CDK 4/6 Inhibition Therapy Management in the Clinical Practice Team ($500,000 award, deadline March 22nd, 2017). It is our intent to support continuing professional development programs (CE/CME) for allied health professionals (nurses, nurse practitioners, physician assistants, medical technicians, etc.) involved in the care and management of patients with advanced or metastatic breast cancer. All members of the clinical practice team play an important role in counseling and supporting patients during therapy, including explaining possible benefits and side effects of different treatments and answering patient questions. Proposed continuing education programs should increase the awareness and understanding of the management of patients with advanced or metastatic breast cancer using CDK 4/6 inhibitors. Possible areas of focus could include: 1) Improving provider/patient communication regarding treatment options, treatment initiation, and management 2) Understanding how patient adherence is monitored and addressed 3) Increasing awareness and understanding of how dose adjustments are implemented in both the clinical trial and real world setting, and 4) Understanding the role a nurse navigator plays in the management of these patients. All activity types will be considered through this CGA, including live events, satellite symposia, workshops, online courses, print materials, and other enduring materials including published proceedings. Efforts should be made to encourage interaction, incorporate real-world patient case discussions, and provide opportunities to extend and reinforce learning opportunities beyond the live setting. Individual projects requesting up to $500,000 will be considered.
Gerber Foundation – Research Awards ($350,000 award, two funding cycle deadlines for Letters of Intent – June 1st and December 1st, 2017). The mission of The Gerber Foundation, to enhance the quality of life of infants and young children in nutrition, care, and development, has remained the guiding beacon for Foundation giving throughout its history. Accordingly, priority is given to projects whose primary beneficiaries are young children from birth to three years of age. The Trustees of The Gerber Foundation expect the Foundation’s grant dollars to make a significant impact on issues facing infants and young children. Through our grant-making efforts, the Trustees are committed to improving the health and well-being of the youngest members of our society. The primary focus, supported by over 70% of grant-making, is applied research focused on health and nutritional issues affecting infants and young children. Research projects aimed at finding solutions to common every-day issues and problems regarding children’s health and nutrition are sought. Of particular interest are those offering a substantial promise of meaningful advances in prevention and treatment of diseases and those with broad applicability to the general population. Awards and time periods vary depending upon the specific project. Research projects may be no longer than 3 years in length. Total grant size should be no more than roughly $350,000. Concept papers are due on June 1 or December 1 of each year. If a full proposal is requested, deadlines are August 15 and February 15, respectively. Novice Researchers: Applications for Novice grants follow the same process as regular grants and are limited to no more than $20,000 in total (inclusive of indirects). They are identified by the amount requested in the application.
Franklin Institute – 2018 Bower Award and Prize for Achievement in Science – Theme: Genome Editing ($250,000 award, Email of Intent deadline April 30th, proposal deadline May 31st, 2017). The Franklin Institute seeks nominations for the 2018 Bower Award and Prize for Achievement in Science of individuals who have made significant contributions to our understanding or the development of genome editing and/or its applications. Nominations may recognize contributions including, but not limited to, the discovery/elucidation of genome editing mechanisms such as those involving CRISPR, TALENs, or zinc finger nucleases; genome editing tool development; or genome editing for basic research or applied outcomes in a variety of systems (e.g. for crop improvement or medical therapeutics). Nominations must clearly indicate the scientific impact of the nominee’s work, whether conceptual, technical, or integrative. Nomination Procedures: An email of intent to nominate sent to email@example.com by April 30, 2017 is appreciated.
Pediatric Epilepsy Research Foundation – Grant for Infrastructure/Registry Research ($200,000 award, Letter of Intent deadline November 30th, 2017). This competitive grant is directed at developing new infrastructure, (registries and networks) in child neurology. To that end, PERF offers the "The PERF Grant for Infrastructure/Registry Research". While we will consider projects in all areas of child neurology, we wish to promote advances in the field of pediatric epilepsy. We look forward to evaluating your exciting and innovative projects. Grant amounts may range up to $200,000.00, awarded over two years.
Anesthesia Patient Safety Foundation – Safety Scientist Career Development Award ($150,000 award, deadline May 1st, 2017). APSF is soliciting applications for training grants to develop the next generation of patient safety scientists. APSF will fund one ($150,000 over 2 years) Safety Scientist Career Development Award to the sponsoring institution of a highly promising new safety scientist.
International Rett Syndrome Foundation – multiple opportunities:
· Basic Research Grant Program ($150,000 award, Letter of Intent deadline May 22nd, 2017). “To correct the biology we first must understand what has gone wrong”. Rettsyndrome.org announces the availability of Regular Research grants for international biomedical research to promote the understanding of MeCP2 in the pathogenesis of the neurobehavioral phenotype of Rett syndrome (RTT). We seek to gain a better understanding of the underlying pathology of the disorder leading to an amelioration of the symptoms and a cure for RTT. The two year Regular research grant awards are meant to (1) provide seed money for research that encompasses innovative therapeutic approaches and cutting-edge diagnostic techniques, (2) design to assist investigators establish careers in fields relevant to Rett syndrome research, and (3) lead to follow-on funding from other agencies. Funding: The maximum funding for this Regular Research grants is $150,000 for two years ($75,000 per year).
· Neuro-Habilitation Research Grant Program ($150,000 award, Letter of Intent deadline May 1st, 2017). “To reset the neurology we must find methods to habilitate cognition, speech, occupational and physical activities”. Neuro-Habilitation HeART (Help Accelerate RTT Therapeutics) grant awards are designed to provide funding for research aimed at maximizing function and abilities in the boys and girls with Rett syndrome. The program specifically targets research for cognitive therapies, physical therapies, occupational therapies and speech therapies, which will directly impact the quality of life for those affected by Rett syndrome. Funding: The maximum funding for HeART awards is $150,000 for two years ($75,000 per year).
· Translational Research Grant Program ($150,000 award, Letter of Intent deadline May 8th, 2017). “To develop treatments that change the biology of Rett Syndrome”. HeART (Help Accelerate RTT Therapeutics) grant awards are designed to promote the development and testing of therapeutics to treat and reverse Rett syndrome (RTT). Awards will be provided for cell-based assay development, early-stage drug discovery and development, early stage medicinal chemistry efforts on high value candidate therapeutics, cell-based screening of candidate therapeutics and follow-on early-stage in vivo testing. Grant applications for exploratory studies towards development of biomarkers or objective clinical outcome measures will also be considered. The goal of this award mechanism is to provide seed funding for early stage drug discovery and development efforts. We encourage novel research programs that broadly encompass the following areas of unmet need: 1) Design, synthesis and testing of potential disease modifying therapeutics to treat or reverse RTT 2) Testing of existing therapeutics both in vitro and in vivo to repurpose their use in RTT 3) Development and/or validation of in vitro and in vivo models of RTT for therapeutic testing, and 4)Development and/or validation of novel biomarkers for objective clinical trials outcome measures.
· Mentored Training Fellowship Program ($100,000 award, deadline June 5th, 2017). “To build the lab bench of future Rett syndrome researchers”. Rettsyndrome.org announces the availability of Mentored Training Fellowships to support scientists early in their career to in both basic and clinical research in the field of Rett syndrome so that they become successful, independent basic research scientists and clinical investigators. The two year Mentored Training fellowships are designed to assist post-doctoral and clinical scientist researcher in training to establish careers in fields relevant to Rett syndrome research. The Fellowship applicant is considered the Principal Investigator (PI) for the application, and is required to identify a sponsoring mentor. We encourage novel basic research programs for Regular Research Grants and Mentored Training Fellowships within the following emphasis areas: 1) Understanding the role of MeCP2 during normal brain development 2) Characterizing the role of MeCP2, including MeCP2 target genes, in normal structure and function of the developing and adult nervous system 3) Determination of the relationship between patterns of expression of MeCP2, FoxG1, CDKL5, and related proteins in the nervous system and the neurologic and behavioral phenotypes of patients with RTT and/or related animal models 4) The investigation of neuronal abnormalities that result from MeCP2 dysfunction 5) The role of microglial and macroglial cells in development as it relates to RTT , and 6) Understanding mechanisms and systems leading to aberrant behavior in RTT.
Prince Mahidol Awards in Medicine and Public Health ($100,000 award, nominations deadline May 31st, 2017). The Prince Mahidol Award, which is conferred to individual(s) or institution(s), is divided into two categories: In Medicine: for outstanding performance and/or research in the field of medicine for the benefit of mankind. In Public Health: for outstanding contribution in the field of public health for the sake of the well-being of the peoples. The Prince Mahidol Award shall consist of a medal, a certificate, and a sum of money as the prize. The prize money for each of the two categories shall be for the sum of US $100,000. Nomination forms shall be submitted to the secretary-general of the Prince Mahidol Award Foundation before May 31 each year.